Before entering into risk-sharing agreements, manufacturers must understand the challenges and implications, writes Kimberly E. White.
Kimberly E. White
Advertisement
Kimberly E. White, MBA is a Vice President at Numerof & Associates, Inc. (Numerof), a strategic management consulting firm focused on organizations in dynamic, rapidly changing industries.
Articles by Kimberly E. White
Advertisement
Latest Updated Articles
- Engaging in Risk-Sharing Agreements with Providers
Published: November 10th 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly’s Jaypirca Achieves Primary Endpoint in Head-to-Head Phase III Study Against Imbruvica Treating CLL/SLL
2
Relation Therapeutics Forms $1.7 Billion Multi-Program Collaboration with Novartis Advancing Therapeutics for Atopic Diseases
3
Is FDA Streamlining Regulations in the Biosimilar Space?
4
Pfizer Enters Exclusive Collaboration and License Agreement with Yao Pharma for Oral Small-Molecule GLP-1 Agonists
5
